Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ziconotide - ESTEVE Pharmaceuticals

Next Previous
Drug Profile

Ziconotide - ESTEVE Pharmaceuticals

Alternative Names: CI 1009; MVIIA; Prialt; SNX 111; SNX 194; Ziconotide acetate - Jazz Pharmaceuticals/ESTEVE Pharmaceuticals

Latest Information Update: 24 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elan Pharmaceuticals
  • Developer Eisai Co Ltd; Elan Pharmaceuticals; ESTEVE Pharmaceuticals; Jazz Pharmaceuticals plc
  • Class Conotoxins; Neuroprotectants; Non-opioid analgesics; Peptides
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pain
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pain
  • Discontinued Craniocerebral trauma; Stroke

Most Recent Events

  • 10 Mar 2026 Esteve acquires Ziconotide from TerSera Therapeutics
  • 06 Nov 2018 Jazz Pharmaceuticals completes the sale of its rights related to ziconotide intrathecal infusion (Prialt) to TerSera Therapeutics in September 2018
  • 02 Jul 2018 Jazz Pharamceuticals enters into a definetive agreement to sell rights related to ziconotide intrathecal infusion to TerSera Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top